| 1 |
唐宇雁， 谢仕斌， 朱建芸. 甲胎蛋白和甲胎蛋白异质体比率（AFP-L3%）对HBV 相关早期肝细胞癌的诊断效能分析 ［J］. 临床肝胆病杂志， 2023， 39 （11）: 2607-2613.
|
| 2 |
Luo P， Wu S， Yu Y， et al. Current status and perspective biomarkers in AFP negative HCC: towards screening for and diagnosing hepatocellular carcinoma at an earlier stage ［J］. Pathol Oncol Res，2020， 26（2）: 599-603.
|
| 3 |
Zhang Z， Zhang Y， Wang Y， et al. Alpha-fetoprotein-L3 and Golgi protein 73 may serve as candidate biomarkers for diagnosing alphafetoprotein-negative hepatocellular carcinoma ［J］. Onco Targets Ther，2015， 9: 123-129.
|
| 4 |
丁华洋， 王兴宇， 刘学谦， 等. GP73 和HSP90α 在低浓度甲胎蛋白原发性肝癌诊断中的应用价值 ［J］. 安徽医科大学学报， 2021， 56（8）: 1291-1294.
|
| 5 |
宋红亮， 王建国， 张会， 等. 血清学标志物甲胎蛋白、PIVKA-Ⅱ和磷脂酰肌醇蛋白聚糖3 联合诊断肝癌的meta 分析 ［J］. 浙江大学学报（医学版）， 2024， 53 （1）: 131-139.
|
| 6 |
Liu S， Wang M， Zheng C， et al.Diagnostic value of serum glypican-3 alone and in combination with AFP as an aid in the diagnosis of liver cancer ［J］. Clin Biochem， 2020， 79: 54-60
|
| 7 |
Song Z， Chen W， Athavale D， et al. Osteopontin takes center stage in chronic liver disease ［J］. Hepatology.2021；73（4）: 1594-1608.
|
| 8 |
da Costa AN， Plymoth A， Santos-Silva D， et al. Osteopontin and latent-TGF β binding-protein 2 as potential diagnostic markers for HBVrelated hepatocellular carcinoma ［J］. Int J Cancer， 2015， 136（1）: 172-181.
|
| 9 |
Zhu M， Zheng J， Wu F， et al. OPN is a promising serological biomarker for hepatocellular carcinoma diagnosis ［J］. J Med Virol，2020， 92（12）: 3596-3603.
|
| 10 |
Wei W， Liu M， Ning S， et al. Diague of plasma HSP90α levels for detection of hepatocellular carcinoma ［J］. BMC Cancer， 2020， 20（1）: 6.
|
| 11 |
Luo P， Yin P， Hua R， et al. A Large-scale， multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma ［J］. Hepatology， 2018， 67（2）: 662-675.
|
| 12 |
Fu Y， Xu X， Huang D， et al. Plasma heat shock protein 90alpha as a biomarker for the diagnosis of liver cancer: An official， large-scale，and multicenter clinical trial ［J］. EBioMedicine， 2017， 24: 56-63.
|
| 13 |
Zhou J， Yang W， Zhang S， et al. Diagnostic value of angiopoietin-like protein 2 for CHB-related hepatocellular carcinoma ［J］. Cancer Manag Res， 2019， 11: 7159-7169.
|
| 14 |
Kim DY， Toan BN， Tan CK， et al. Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region ［J］. Clin Mol Hepatol， 2023， 29（2）: 277-292.
|
| 15 |
Liu Z， Wu M， Lin D， et al. Des-gamma-carboxyprothrombin is a favorable biomarker for the early diagnosis of alfa-fetoproteinnegative hepatitis B virus-related hepatocellular carcinoma ［J］. J Int Med Res， 2020， 48（2）: 300060520902575.
|
| 16 |
段聪明. a-L-岩藻糖苷酶在原发性肝癌中的诊断价值 ［J］. 实用医技杂志， 2006， 13（24）: 4332-4334.
|
| 17 |
Shu H， Li W， Shang S， et al. Diagnosis of AFP-negative early-stage hepatocellular carcinoma using Fuc-PON1 ［J］. Discov Med， 2017，23（126）: 163-168.
|
| 18 |
Ye X， Li C， Zu X， et al. A large-scale multicenter study validates aldoketo reductase family 1 member B10 as a prevalent serum marker for detection of hepatocellular carcinoma ［J］. Hepatology， 2019， 69（6）:2489-2501.
|
| 19 |
Liu P， Lu D， Al-Ameri A， et al. Glutamine synthetase promotes tumor invasion in hepatocellular carcinoma through mediating epithelialmesenchymal transition ［J］. Hepatol Res， 2020， 50（2）: 246-257.
|
| 20 |
Song X， Wu A， Ding Z， et al. Soluble Axl is a novel diagnostic biomarker of hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus Infection ［J］. Cancer Res Treat， 2020， 52（3）:789-797.
|
| 21 |
Lu Q， Li J， Cao H， et al. Comparison of diagnostic accuracy of Midkine and AFP for detecting hepatocellular carcinoma: a systematic review and meta-analysis ［J］. Biosci Rep， 2020， 40（3）: BSR20192424.
|
| 22 |
Zheng L， Li H， Huang J， et al. Serum midkine levels for the diagnosis and assessment of response to interventional therapy in patients with hepatocellular carcinoma ［J］. J Interv Med， 2020， 4（1）: 39-45.
|
| 23 |
Song BC， Chung YH， Kim JA， et al. Transforming growth factor-beta1 as a useful serologic marker of small hepatocellular carcinoma ［J］.Cancer， 2002， 94（1）: 175-180.
|
| 24 |
Gu Y， Li X， Bi Y， et al. CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma ［J］. Aging （Albany NY）， 2020， 12（1）: 784-807.
|
| 25 |
Sadeghi M， Lahdou I， Oweira H， et al. Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the presence of hepatocellular carcinoma ［J］. Br J Cancer， 2015， 113（5）: 756-762.
|
| 26 |
Kong L， Zhou Y， Bu H， et al. Deletion of interleukin-6 in monocytes/macrophages suppresses the initiation of hepatocellular carcinoma in mice ［J］. J Exp Clin Cancer Res， 2016， 35（1）: 131.
|
| 27 |
Witjes CD， van Aalten SM， Steyerberg EW， et al. Recently introduced biomarkers for screening of hepatocellular carcinoma: a systematic review and meta-analysis ［J］. Hepatol Int， 2013， 7（1）: 59-64.
|
| 28 |
马文文， 呼敏， 王贵红， 等. miR-103a-2、miR-122 和vaspin 在非酒精性脂肪性肝病合并HBV 感染中的表达及意义 ［J/OL］. 中华临床医师杂志（电子版）， 2022， 16（2）: 170-174.
|
| 29 |
Malik J， Klammer M， Rolny V， et al. Comprehensive evaluation of microRNA as a biomarker for the diagnosis of hepatocellular carcinoma ［J］. World J Gastroenterol， 2022， 28（29）: 3917-3933.
|
| 30 |
Tian Z， Yu T， Wei H， et al. Clinical value of LHPP-associated microRNAs combined with protein induced by vitamin K deficiency or antagonist-II in the diagnosis of alpha-fetoprotein-negative hepatocellular carcinoma ［J］. J Clin Lab Anal， 2020， 34（2）: e23071.
|
| 31 |
Zhou J， Yu L， Gao X， et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma ［J］. J Clin Oncol，2011， 29（36）: 4781-4788.
|
| 32 |
Yu J， Ding WB， Wang MC， et al. Plasma circular RNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma: A largescale， multicenter study ［J］. Int J Cancer， 2020， 146（6）: 1754-1763.
|
| 33 |
侯志远， 刘源， 杨超然， 等. 循环肿瘤DNA 在肝细胞癌中的研究现状及展望 ［J］. 临床肝胆病杂志， 2022， 38 （11）: 2616-2620.
|
| 34 |
Xiong Y， Xie CR， Zhang S， et al. Detection of a novel panel of somatic mutations in plasma cell-free DNA and its diagnostic value in hepatocellular carcinoma ［J］. Cancer Manag Res， 2019， 11: 5745-5756.
|
| 35 |
Zhu H. Squamous cell carcinoma antigen: clinical application and research status ［J］. Diagno stics （Basel）， 2022， 12（5）: 1065.
|
| 36 |
Giannelli G， Fransvea E， Trerotoli P， et al. Clinical validation of combined serological biomarkers for improved hepatocellular carcinoma diagnosis in 961 patients ［J］. Clin Chim Acta， 2007， 383（1-2）: 147-152.
|
| 37 |
Ezzikouri S， Kimura K， Sunagozaka H， et al. Serum DHCR24 autoantibody as a new biomarker for progression of hepatitis C ［J］.EBioMedicine， 2015， 2（6）: 604-612.
|
| 38 |
Yi CH， Weng HL， Zhou FG， et al. Elevated core-fucosylated IgG is a new marker for hepatitis B virus-related hepatocellular carcinoma ［J］.Oncoimmunology， 2015， 4（12）: e1011503.
|
| 39 |
Nomura F， Sogawa K， Noda K， et al. Serum anti-Ku86 is a potential biomarker for early detection of hepatitis C virus-related hepatocellular carcinoma ［J］. Biochem Biophys Res Commun， 2012， 21（4）: 837-843.
|